MS
58
-3
DD
53
-7
LEG
31
-6
FMC
41
5
SLG
55
-4
CTAS
49
3
QCOM
51
-5
SYY
50
-3
ZTS
54
-4
GOOG
81
10
NUE
47
-4
MLM
44
-3
PCAR
55
3
AMP
52
-2
DLTR
54
3
AON
34
-2
BBY
46
3
MAS
56
-6
AMAT
40
-3
PEG
53
-2
MS
58
-3
DD
53
-7
LEG
31
-6
FMC
41
5
SLG
55
-4
CTAS
49
3
QCOM
51
-5
SYY
50
-3
ZTS
54
-4
GOOG
81
10
NUE
47
-4
MLM
44
-3
PCAR
55
3
AMP
52
-2
DLTR
54
3
AON
34
-2
BBY
46
3
MAS
56
-6
AMAT
40
-3
PEG
53
-2
Financhill
Back

4D Molecular Therapeutics 10K Form

Buy
51

FDMT
4D Molecular Therapeutics

Last Price:
6.90
Seasonality Move:
19.19%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2021-03-25 10K FDMT/4D Molecular Therapeutics Annual

Receive FDMT News And Ratings

See the #1 stock for the next 7 days that we like better than FDMT

FDMT Financial Statistics

Sales & Book Value

Annual Sales: $20.72M
Cash Flow: $-31.17M
Price / Cash Flow: 0
Annual Sales: $10.63
Price / Book: 0.61

Profitability

EPS (TTM): -2.85000
Net Income (TTM): $-143.48M
Gross Margin: --
Return on Equity: -30.15%
Return on Assets: -28.07%

4D Molecular Therapeutics Earnings Forecast

Key 4D Molecular Therapeutics Financial Ratios

  • The Research & Development expenses have been 468.54% of Revenue.
  • The Net Earning history of FDMT is -486.59% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 2 years.

4D Molecular Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: FDMT
CUSIP: 35104E
Website: 4dmoleculartherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 17.33
Quick Ratio: 17.03

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

FDMT Technical Analysis vs Fundamental Analysis

Buy
51
4D Molecular Therapeutics (FDMT) is a Buy

Is 4D Molecular Therapeutics a Buy or a Sell?